IL105472A - Medicinal composition for suppressing T-cell proliferation and immune response to foreign tissue transplantation, containing antigens from the primary type II transplant antigen complex or synthetic peptides - Google Patents
Medicinal composition for suppressing T-cell proliferation and immune response to foreign tissue transplantation, containing antigens from the primary type II transplant antigen complex or synthetic peptidesInfo
- Publication number
- IL105472A IL105472A IL10547293A IL10547293A IL105472A IL 105472 A IL105472 A IL 105472A IL 10547293 A IL10547293 A IL 10547293A IL 10547293 A IL10547293 A IL 10547293A IL 105472 A IL105472 A IL 105472A
- Authority
- IL
- Israel
- Prior art keywords
- mammal
- class
- peptide
- antigen
- histocompatibility complex
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
- C07K14/70539—MHC-molecules, e.g. HLA-molecules
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/26—Lymph; Lymph nodes; Thymus; Spleen; Splenocytes; Thymocytes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/28—Bone marrow; Haematopoietic stem cells; Mesenchymal stem cells of any origin, e.g. adipose-derived stem cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/001—Preparations to induce tolerance to non-self, e.g. prior to transplantation
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Immunology (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Cell Biology (AREA)
- Engineering & Computer Science (AREA)
- Zoology (AREA)
- Developmental Biology & Embryology (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Organic Chemistry (AREA)
- Biomedical Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Virology (AREA)
- Biotechnology (AREA)
- Transplantation (AREA)
- Genetics & Genomics (AREA)
- Hematology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Toxicology (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Plant Substances (AREA)
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US87128992A | 1992-04-20 | 1992-04-20 | |
US96177992A | 1992-10-15 | 1992-10-15 | |
US97773792A | 1992-11-13 | 1992-11-13 | |
US08/027,127 US5593698A (en) | 1990-10-31 | 1993-03-05 | Suppression of proliferative response and induction of tolerance with polymorphic class II MHC allopeptides |
Publications (2)
Publication Number | Publication Date |
---|---|
IL105472A0 IL105472A0 (en) | 1993-08-18 |
IL105472A true IL105472A (en) | 1999-06-20 |
Family
ID=27487557
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
IL10547293A IL105472A (en) | 1992-04-20 | 1993-04-20 | Medicinal composition for suppressing T-cell proliferation and immune response to foreign tissue transplantation, containing antigens from the primary type II transplant antigen complex or synthetic peptides |
Country Status (13)
Country | Link |
---|---|
US (1) | US5593698A (hu) |
EP (1) | EP0637249B1 (hu) |
JP (1) | JPH07505892A (hu) |
KR (1) | KR100275656B1 (hu) |
AT (1) | ATE205400T1 (hu) |
AU (1) | AU686101B2 (hu) |
BR (1) | BR9306345A (hu) |
CA (1) | CA2118502A1 (hu) |
DE (1) | DE69330752D1 (hu) |
HU (1) | HUT71310A (hu) |
IL (1) | IL105472A (hu) |
NO (1) | NO943967D0 (hu) |
WO (1) | WO1993020842A1 (hu) |
Families Citing this family (21)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
IL99699A (en) | 1990-10-10 | 2002-04-21 | Autoimmune Inc | Drug with the option of oral, intra-intestinal, or inhaled dosing for suppression of autoimmune response associated with type I diabetes |
US6156306A (en) * | 1994-08-17 | 2000-12-05 | Albert Einstein College Of Medicine Of Yeshiva University | Pancreatic β-cells for allogeneic transplantation without immunosuppression |
GB9505784D0 (en) * | 1995-03-22 | 1995-05-10 | Lynxvale Ltd | Anti-tumour treatment |
US7361331B2 (en) * | 1996-10-18 | 2008-04-22 | Her Majesty The Queen In Right Of Canada, As Represented By The Minister Of Agriculture And Agri-Food | Plant bioreactors |
US6617171B2 (en) * | 1998-02-27 | 2003-09-09 | The General Hospital Corporation | Methods for diagnosing and treating autoimmune disease |
US6599710B1 (en) | 1999-03-10 | 2003-07-29 | The General Hospital Corporation | Treatment of autoimmune disease |
WO2001076617A2 (en) * | 2000-03-15 | 2001-10-18 | Advanced Research And Technology Institute | Oral tolerance induction by collagen to prevent allograft rejection |
US7348005B2 (en) * | 2000-03-15 | 2008-03-25 | Advanced Research And Technology Institute | Oral tolerance induction by collagen to prevent allograft rejection |
ATE367823T1 (de) | 2000-05-24 | 2007-08-15 | Us Health | E-selectin zur behandlung oder vorbeugung von schlaganfall |
HU229377B1 (hu) | 2000-08-21 | 2013-11-28 | Apitope Technology Bristol Ltd | Tolerogén humán peptidek |
US7582313B2 (en) * | 2002-06-27 | 2009-09-01 | The General Hospital Corporation | Methods of organ regeneration using Hox 11-expressing pluripotent cells |
US7628988B2 (en) | 2002-06-27 | 2009-12-08 | The General Hospital Corporation | Methods and compositions for treating type 1 diabetes |
WO2004045376A2 (en) * | 2002-11-15 | 2004-06-03 | The General Hospital Corporation | Screening methods to identify treatments for autoimmune disease |
US20080102054A1 (en) * | 2005-01-18 | 2008-05-01 | Faustman Denise L | Compositions Containing Agm Cells And Methods Of Use Thereof |
GB0710529D0 (en) | 2007-06-01 | 2007-07-11 | Circassia Ltd | Vaccine |
SI2190473T1 (sl) | 2007-08-15 | 2013-05-31 | Circassia Limited | Peptid z zmanjšano tvorbo dimerov |
EP3936137A1 (en) | 2013-02-07 | 2022-01-12 | The General Hospital Corporation | Methods for expansion or depletion of t-regulatory cells |
ES2702676T3 (es) * | 2014-04-01 | 2019-03-04 | Inst Nat Sante Rech Med | Péptido de donante aislado derivado de MHC y usos del mismo |
HRP20231392T1 (hr) | 2015-05-15 | 2024-04-26 | The General Hospital Corporation | Antagonistička protutijela na superobitelj receptora za faktor tumorske nekroze |
EP3355914B1 (en) | 2015-09-29 | 2024-03-06 | The General Hospital Corporation | A composition comprising bcg for reducing cholesterol. |
CN116715767A (zh) | 2016-05-13 | 2023-09-08 | 综合医院公司 | 拮抗性抗肿瘤坏死因子受体超家族抗体 |
Family Cites Families (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5364762A (en) * | 1990-03-21 | 1994-11-15 | Board Of Trustees Of The Leland Stanford Junior University | Major histocompatibility complex (MHC) molecules |
-
1993
- 1993-03-05 US US08/027,127 patent/US5593698A/en not_active Expired - Fee Related
- 1993-04-20 KR KR1019940703715A patent/KR100275656B1/ko not_active IP Right Cessation
- 1993-04-20 EP EP93910671A patent/EP0637249B1/en not_active Expired - Lifetime
- 1993-04-20 DE DE69330752T patent/DE69330752D1/de not_active Expired - Lifetime
- 1993-04-20 IL IL10547293A patent/IL105472A/en not_active IP Right Cessation
- 1993-04-20 BR BR9306345A patent/BR9306345A/pt not_active Application Discontinuation
- 1993-04-20 WO PCT/US1993/003708 patent/WO1993020842A1/en active IP Right Grant
- 1993-04-20 AU AU41083/93A patent/AU686101B2/en not_active Ceased
- 1993-04-20 JP JP5518673A patent/JPH07505892A/ja not_active Ceased
- 1993-04-20 AT AT93910671T patent/ATE205400T1/de not_active IP Right Cessation
- 1993-04-20 HU HU9403006A patent/HUT71310A/hu unknown
- 1993-04-20 CA CA002118502A patent/CA2118502A1/en not_active Abandoned
-
1994
- 1994-10-19 NO NO943967A patent/NO943967D0/no not_active Application Discontinuation
Also Published As
Publication number | Publication date |
---|---|
JPH07505892A (ja) | 1995-06-29 |
ATE205400T1 (de) | 2001-09-15 |
IL105472A0 (en) | 1993-08-18 |
EP0637249A4 (en) | 1997-01-08 |
KR950701228A (ko) | 1995-03-23 |
AU686101B2 (en) | 1998-02-05 |
EP0637249A1 (en) | 1995-02-08 |
EP0637249B1 (en) | 2001-09-12 |
HUT71310A (en) | 1995-11-28 |
CA2118502A1 (en) | 1993-10-28 |
US5593698A (en) | 1997-01-14 |
DE69330752D1 (de) | 2001-10-18 |
WO1993020842A1 (en) | 1993-10-28 |
NO943967L (no) | 1994-10-19 |
AU4108393A (en) | 1993-11-18 |
NO943967D0 (no) | 1994-10-19 |
HU9403006D0 (en) | 1994-12-28 |
BR9306345A (pt) | 1998-06-30 |
KR100275656B1 (ko) | 2000-12-15 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US5593698A (en) | Suppression of proliferative response and induction of tolerance with polymorphic class II MHC allopeptides | |
Sayegh et al. | Role of indirect allorecognition in allograft rejection | |
Allez et al. | Regulatory T cells: peace keepers in the gut | |
SAYEGH et al. | Thymic recognition of class II major histocompatibility complex allopeptides induces donor-specific unresponsiveness to renal allografts | |
US5681556A (en) | Method and compositions for suppressing allograft rejection in mammals | |
Dong et al. | Transplantation tolerance: the concept and its applicability | |
CA2110055C (en) | T cell receptor peptides as therapeutics for immune-related disease | |
Miller et al. | Suppression of experimental autoimmune encephalomyelitis by oral administration of myelin basic protein VI. Suppression of adoptively transferred disease and differential effects of oral vs. intravenous tolerization | |
Miller et al. | Tolerance and suppressor mechanisms in experimental autoimmune encephalomyelitis: implications for immunotherapy of human autoimmune diseases | |
Brouard et al. | T cell response in xenorecognition and xenografts: a review | |
Zavazava et al. | Oral feeding of an immunodominant MHC donor-derived synthetic class I peptide prolongs graft survival of heterotopic cardiac allografts in a high-responder rat strain combination | |
Chowdhury et al. | Comparative studies of specific acquired systemic tolerance induced by intrathymic inoculation of a single synthetic Wistar-Furth (RT1u) allo-MHC class I (RT1. AU) peptide or WAG (RT1u)-derived class I peptide1 | |
Murphy et al. | T CELL RECOGNITION OF XENO-MHC PEPTIDES DURING CONCORDANT XENOGRAFT REJECTION1 | |
Kelley et al. | Renal tubular epithelial and T cell interactions in autoimmune renal disease. | |
Saitovitch et al. | RECIPIENT CELLS EXPRESSING SINGLE DONOR MHC LOCUS PRODUCTS CAN SUBSTITUTE FOR DONOR-SPECIFIC TRANSFUSION IN THE INDUCTION OF TRANSPLANTATION TOLERANCE WHEN PRETREATMENT IS COMBINED WITH ANTI-CD4 MONOCLONAL ANTIBODY: Evidence for a Vital Role of Cd4:+: T Cells in the Induction of Tolerance to Class I Molecules: 1:: 2 | |
Kroemer et al. | The fail-safe paradigm of immunological self-tolerance | |
NOEL | The immune response in autoimmunity and autoimmune disease | |
Oluwole et al. | CD4+ CD25+ regulatory T cells mediate acquired transplant tolerance | |
Saborio et al. | Regulatory T cells maintain peripheral tolerance to islet allografts induced by intrathymic injection of MHC class I allopeptides | |
EP0883406A1 (fr) | Utilisation de l'il-7 dans le traitement des maladies auto-immunes, en particulier le diabete mellitus insulinodependant | |
Masroor et al. | Induction of tolerance in rodent cardiac allotransplantation using an MHC class I-derived peptide and cyclosporin A | |
Ten Berge et al. | A longitudinal study on the effects of azathioprine and high doses of prednisone on the immune system of kidney-transplant recipients | |
Kozovska et al. | TT cellular interaction between CD4-CD8-regulatory T cells and T cell clones presenting TCR peptide. Its implication for TCR vaccination against experimental autoimmune encephalomyelitis. | |
Murphy et al. | Immunomodulatory function of major histocompatibility complexderived peptides | |
Benichou et al. | The influence of two distinct alloresponse pathways on the design of peptide-based strategies for allograft tolerance |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FF | Patent granted | ||
KB | Patent renewed | ||
KB | Patent renewed | ||
MM9K | Patent not in force due to non-payment of renewal fees |